Gastrointestinal Diseases

Responsable de Grupo: Luis Bujanda, M.D., Ph.D.

Donostialdea IHO
Dr. Luis Bujanda Fernández de Piérola has a Degree in Medicine and Surgery from the University of Navarra and is a Specialist in the Digestive System. Chair of Medicine at the University of the Basque Country (UPV/EHU) since 2019. Head of the Digestive System Service at the Donostia University Hospital (Donostialdea IHO) in the period 2011-2017. Dr. Bujanda is Leader of the Gastrointestinal and Liver Diseases Group at the Biodonostia HRI and of the Research Group in Gastrointestinal Diseases since 2008. He is also Leader of the CIBERehd (Network Centre for Biomedical Research in Liver and Digestive Diseases) Research Group since 2008, former President of the Spanish Association of Gastroenterology (2016-2020) and current President of the Spanish Foundation of Gastroenterology. Today Dr. Bujanda has more than 385 publications in PubMed, with an h-index of 49 and more than 8,500 citations, 1,500 of which date from 2020. He has directed 13 doctoral theses, two of them international.

Strategic Objectives

  • Gastrointestinal Oncology: Cancer is the primary cause of death in men and the second in women. Colorectal cancer (CRC) is the most common tumour as regards incidence and the second as regards mortality.
    • To determine which test is best for the early diagnosis of this disease and aspects to improve its acceptance and quality.
      • To compare the efficacy of screening using the immunological method of detecting faecal occult blood (FOB) with a colonoscopy in the intermediate risk population (asymptomatic individuals aged 50-69 years with no personal or family history of CRC) to detect CRC or advanced adenomas, in a first round of screening.
      • To assess new biochemical markers for the early diagnosis of colon cancer.
      • To assess the colonoscopy and FOB in first degree relatives of CRC.
    • To determine the genetic factors that foster its appearance, the response to treatment and the adverse effects of treatment (Epicolon I, Epicolon II, Epipolip, Epineo, Colonprev, Smarthealth and Epicolon III studies).
    • Search for new therapeutic targets in pancreatic cancer, cholangiocarcinoma, hepatocarcinoma and gastric cancer.
  • Other digestive diseases: Our objective is to continue to stand out as a group in the Helicobacter pylori pathology (diagnosis and treatment), in research into the secondary gastrointestinal effects produced by the anti-inflammatories, and in other areas, such as ischemic colitis or inflammatory bowel disease.

Main lines of research

  • Gastrointestinal Oncology.
    • Colon cancer (CRC) screening.
    • Molecular bases of hereditary and familial colorectal cancer. Diagnostic and therapeutic implications.
    • Pancreatic cancer.
    • Gastric cancer
  • Inflammatory Bowel Disease
    • To study the prevalence of hepatitis infection in patients with inflammatory bowel disease.
  • Gastrointestinal Diseases: Helicobacter Pylori and other diseases.
    • Treatment and evolution of patients with Helicobacter pylori infection.

Team Members

Name Surname
Center E-mail
Horacio Alonso Galán OSI Donostialdea
Maialen Barrero Iñiguez Onkologikoa
Jose María Enríquez Navascues OSI Donostialdea
Ines Gil Lasa OSI Donostialdea
Ana Goitia Viaña OSI Donostialdea
Elizabeth Hijona Muruamendiaraz IIS Biodonostia
Laura Izquierdo Sánchez IIS Biodonostia

Scientific Output


Page under construction.
We are working to show the Projects and Patents.
We apologize for any inconvenience caused